Enanta Pharmaceuticals | ENTA - Sales Revenues


Enanta Pharmaceuticals reported $16.96M in Sales Revenues for its fiscal quarter ending in December of 2024.





Sales Change Date
AbbVie USD 16.99B 1.99B Jun/2026
Amgen USD 10.1B 1.48B Jun/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 75.23M 1.49M Jun/2026
AstraZeneca USD 15.38B 90M Jun/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
Biogen USD 2.74B 490M Jun/2026
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Gilead Sciences USD 7.8B 800M Jun/2026
GlaxoSmithKline GBP 8.41B 781M Jun/2026
Halozyme Therapeutics USD 481M 104M Jun/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Incyte USD 1.67B 400M Jun/2026
Insmed USD 425.49M 119.53M Jun/2026
Ionis Pharmaceuticals USD 268M 22M Jun/2026
J&J USD 25.31B 1.21B Jun/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
Ligand Pharmaceuticals USD 83.7M 31.98M Jun/2026
Merck USD 16.6B 310M Jun/2026
Neurocrine Biosciences USD 959M 148M Jun/2026
Novartis USD 14.41B 1.3B Jun/2026
Novavax USD 147.14M 76.69M Dec/2025
Pfizer USD 15.03B 530M Jun/2026
PTC Therapeutics USD 361M 88M Jun/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sarepta Therapeutics USD 401.3M 329.5M Jun/2026
Vertex Pharmaceuticals USD 3.33B 340M Jun/2026